XNAS · Healthcare · Biotechnology
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.49 | -0.71 | -44.90% | $0 | ❌ Miss | -1.51% | -7.97% | — |
| 2026-02-26 | Q4 2025 | -0.47 | -0.50 | -6.38% | $0 | ❌ Miss | +0.50% | +1.50% | +3.41% |
Showing last 2 quarters.